Randomized phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel combination therapy for locally advanced pancreatic cancer (JCOG1407, LAPC-mFOLFIRINOX/GnP-rP2) - Randomized phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel combination therapy for locally advanced pancreatic cancer (JCOG1407, LAPC-mFOLFIRINOX/GnP-rP2)

Japan Clinical Oncology Group (JCOG)0 个研究点目标入组 124 人开始时间: 2016年7月13日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1) Synchronous or metachronous (within 5 years) malignancies. 2) Infectious disease requiring systemic treatment. 3) Pyrexia of 38 degrees centigrade or higher. 4) Female during pregnancy, within 28 days of postparturition, or during lactation and male expecting partner's pregnancy. 5) Severe psychological disorder. 6) Receiving continuous systemic corticosteroid or immunosuppressant treatment. 7) Interstitial pneumonia, pulmonary fibrosis, or severe emphysema on chest CT 8) Severe comorbidities (such as heart failure, renal failure, hepatic failure, paresis of intestine, illeus, poorly controlled diabetes and poorly controlled hypertension) 9) History of unstable angina pectoris or myocardial infarction within 6 months before registration. 10) Allergy to iodine and gadolinium

发起方

Japan Clinical Oncology Group (JCOG)